[1]李诗运,谭本旭,戴儒奇,等.优甲乐和稳定性碘干预131I致大鼠甲状腺功能减低的研究[J].国际放射医学核医学杂志,2007,31(6):325-328.
　LI Shi-yun,TAN Ben-xu,DAI Ru-qi,et al.Interventions of euthyrox and stable iodine in hypothyroid occurrence of rats treated with 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(6):325-328.
点击复制

优甲乐和稳定性碘干预131I致大鼠甲状腺功能减低的研究(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
31
期数:
2007年第6期
页码:
325-328
栏目:
实验核医学
出版日期:
1900-01-01

文章信息/Info

Title:
Interventions of euthyrox and stable iodine in hypothyroid occurrence of rats treated with 131I
作者:
李诗运1;  谭本旭1;  戴儒奇1;  姚爱珠1;  白殿卿2;  韩景辉3
1. 570311 海口, 海南省人民医院核医学科;
2. 570311 海口, 海南省实验动物中心;
3. 570311 海口, 海南省人民医院检验科
Author(s):
LI Shi-yun1;  TAN Ben-xu1;  DAI Ru-qi1;  YAO Ai-zhu1;  BAI Dian-qing2;  HAN Jing-hui3
1. Department of Nuclear Medicine, Hainan Province Hospital, Haikou 570311, China;
2. The Laboratory Animal Centen of Hainan Province, Haikou 570311, China;
3. Department of Laboratory, Hainan Province Hospital, Haikou 570311, China
关键词:
甲状腺功能减退症; 碘放射性同位素; 甲状腺素; 稳定性碘; 药物疗法
Keywords:
Hypothroidism; Iodine radioisotope; Thyroxine; Stable iodine; Pharmacotherapy
分类号:
R817.5
摘要:
目的 探讨优甲乐和稳定性碘对131I处理实验鼠后致甲减的影响,为临床131I治疗甲亢和非毒性甲状腺肿提供参考。方法 54只Wistar大鼠平均分成三组,三组均按甲状腺质量计算131I给予剂量,A组单纯给予131I作为对照组;B组于131I处理后第20日起连续给予优甲乐片,共计30d;C组在131I处理后24h给予稳定性碘10μmol。三组给131I后15,60,90d测定血清三碘甲腺原氨酸(T3)、甲状腺素(T4)及促甲状腺激素(TSH)水平,并取甲状腺组织切片计数每高倍镜视野下甲状腺细胞数。结果 131I处理后15d,三组甲状腺细胞计数及各项功能观察指标均无统计学差异。随着时间推移。三组之间出现统计学差异:60d时C组T4低于B组(q=5.16,P<0.05);90d时C组游离T4、总T4低于A、B两组(q值分别为3.31和7.69,P<0.05)。结论 131I处理后早期对大鼠给予优甲乐片十预能有效改善甲状腺滤泡的受损情况,从而降低甲减的发生;大鼠131I处理后24h给予稳定性碘干预则加重131I对甲状腺的损伤。
Abstract:
Objective To investigate the effects of stable iodine and thyroxin on the hypothyroid occurrence of rats treated with 131I thus to provide reference in clinical 131I therapy for hyperthyroid and nontoxic goiter. Methods 54 Wistar rats are equally divided into three groups, whose 131I dose can be calculated by their mass. Group A accept only 131I as contrast, group B accept Euthyrox (200 pg/d, 30d) after 131I treatment, group C accept 10μmol stable iodine 24 h after 131I theatment. Serum triiodothyronine (T3), thyroxine (T4), thyroid-stimulating hormone (TSH) are measured and cell numbers per high power lens(4×100)are counted in 15, 60, 90 d following 131I treatment respectively. All the data are analysed by Fisher test and q test. Results 15 d posttreatment, neither cell numbers nor serum T3, T4 and TSH among three groups has statistically variance. With time prolonging, serum T3, T4 of group C decreased quicker than the other two groups (in 60 d, T4 of group C is less than group B, q=5.16, P<0.05; in 90 d, T4 of group C is less than group A and B, q value is 3.31 and 7.69 respectively, P<0.05). Conclusions Giving the rats euthyrox in time post 131I treatment can not only alleviate the damage in thyroid cells from β-rays, but also decrease the incidence of hypothyroid. On the other hand, giving the rats stable iodine simultaneously probably can prolong the effective half-life of 131I, thus aggravate the damages and increase the incidence of hypothyroid.

参考文献/References:

1 Verger P, Aurengo A, Geoffroy B, et al. Iodine kinetics and effectiveness of stable iodine prophylaxis after intake of radioactive iodine:a review. Thyroid, 2001, 11(4):353-360.
2 熊玲静,梁昌华.甲亢131I治疗后早发甲低相关因素分析.中华核医学杂志,2002,22(6):354-355.
3 魏泓.实验动物学.第一版.成都:四川科学技术出版社,1998.163.
4 Takamura N, Nakamura Y, Ishigaki K, et al. Thyroid blockade during a radiation emergency in iodine-rich areas:effect of stableiodine dosage.Radiat Res, 2004, 45(2):201-204.
5 Le Guen B, Hemidy PY, Garcier Y, et al. French approach for the iodine tablets in the vicinity of nuclear power plants. Health Phys, 2002, 83(2):293-300.

相似文献/References:

[1]梁雯丽,郑艳,李娜,等.Graves甲亢患者131I治疗后早期TRAb及TSAb变化的研究分析[J].国际放射医学核医学杂志,2016,40(1):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
　Liang Wenli,Zheng Yan,Li Na,et al.Analysis of the changes in early TRAb and TSAb after 131I treatment for patients with Graves hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):13.[doi:10.3760/cma.j.issn.1673-4114.2016.01.003]
[2]邓艳,张伟.125I-碘酞酸盐临床应用进展[J].国际放射医学核医学杂志,2016,40(3):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
　Deng Yan,Zhang Wei.125I-iothalamate clinical applications[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):225.[doi:10.3760/cma.j.issn.1673-4114.2016.03.012]
[3]田琦,蒋宁一,郑丽.265例精细个体化131I治疗Graves甲亢的疗效观察[J].国际放射医学核医学杂志,2016,40(4):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
　Tian Qi,Jiang Ningyi,Zheng Li.Therapeutic effect of fine individual 131I treatment on Graves disease hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):259.[doi:10.3760/cma.j.issn.1673-4114.2016.04.004]
[4]贾强,孟召伟,谭建.异位甲状腺发病机理、诊断与治疗的研究进展[J].国际放射医学核医学杂志,2016,40(4):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
　Jia Qiang,Meng Zhaowei,Tan Jian.Progress of pathogenisis, diagnosis and treatment of ectopic thyroid[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):297.[doi:10.3760/cma.j.issn.1673-4114.2016.04.012]
[5]杨珂,唐波,于夕荣,等.甲状腺癌131i治疗病房的辐射屏蔽计算与评价[J].国际放射医学核医学杂志,2015,39(5):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
　yang ke,tang bo,yu xirong,et al.shielding calculation and assessment in 131i therapy for thyroid cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):405.[doi:10. 3760 / cma. j. issn. 1673-4114. 2015. 05. 012]
[6]刘娇,程兵,常伟,等.非高危分化型甲状腺癌低剂量和高剂量131I清甲疗效的分析[J].国际放射医学核医学杂志,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
　Liu Jiao,Cheng Bing,Chang Wei,et al.Ablation efficacy in non-high-risk differentiated thyroid carcinoma patients with low-dose and high-dose 131I[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):419.[doi:10.3760/cma.j.issn.1673-4114.2016.06.004]
[7]徐蓉生,梅艳,赵力威,等.B超引导下术中125I粒子植入治疗晚期胰腺癌的疗效评价[J].国际放射医学核医学杂志,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
　Xu Rongsheng,Mei Yan,Zhao Liwei,et al.Evaluation of 125I particle implantation in the treatment of patients with advanced pancreatic neoplasms using B ultrasound-guided surgery[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):424.[doi:10.3760/cma.j.issn.1673-4114.2016.06.005]
[8]王越,晋建华,李思进,等.甲状腺24h摄碘率与131I治疗Graves甲亢疗效相关性研究[J].国际放射医学核医学杂志,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
　Wang Yue,Jin Jianhua,Li Sijin,et al.Correlation between thyroid 24 h of radioactive iodine uptake and clinical efficacy of 131I therapy for Graves’ hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):442.[doi:10.3760/cma.j.issn.1673-4114.2015.06.002]
[9]郭坤,高蕊,于燕,等.表皮生长因子受体基因表达与甲状腺功能亢进症131I治疗预后的关系[J].国际放射医学核医学杂志,2015,39(1):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
　Guo Kun,Gao Rui,Yu Yan,et al.The relationship between epidermal growth factor receptor mRNA expression and the efficacv of 131I treatment in hyperthyroidism patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):4.[doi:10.3760/cma.j.issn.1673-4114.2015.01.003]
[10]赵腾,梁军,林岩松.131I治疗前刺激性Tg在分化型甲状腺癌风险评估及治疗决策中的意义[J].国际放射医学核医学杂志,2015,39(1):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
　Zhao Teng,Liang Jun,Lin Yansong.The role of preablative stimulated thyroglobulin in guiding risk estimation and therapeutic decisions of differentiated thyroid carcinoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):61.[doi:10.3760/cma.j.issn.1673-4114.2015.01.013]
[11]陈雪梅,周树云,范源,等.表没食子儿茶素没食子酸酯对131I辐射损伤所致甲减大鼠模型抗氧化体系的保护作用[J].国际放射医学核医学杂志,2015,39(4):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
　Chen Xuemei,Zhou Shuyun,Fan Yuan,et al.Protection of antioxidant system of EGCG on the thyroid in rat model from 131I radiation damage[J].International Journal of Radiation Medicine and Nuclear Medicine,2015,39(6):311.[doi:10.3760/cma.j.issn.1673-4114.2015.04.009]
[12]陈再君,蒋宁一.131I治疗甲亢后致甲减的研究变迁[J].国际放射医学核医学杂志,2004,28(4):153.
　CHEN Zai-jun,JIANG Ning-yi.The research vicissitudes of hypothyroidism after 131I therapy for hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):153.
[13]李诗运.131I治疗甲亢后甲减的综合预防和处理措施[J].国际放射医学核医学杂志,2004,28(4):157.
　LI Shi-yun.Synthetic prevention and treatment for hypothyroidism after rdioiodine therapy hyperthyroidism[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):157.
[14]徐颖,徐晓辉.131I治疗甲亢后的继发甲减及替代治疗[J].国际放射医学核医学杂志,2004,28(6):265.
　XU Ying,XU Xiao-hui.The secondary hypothyroidism after radioiodine therapy and the replacement treatment[J].International Journal of Radiation Medicine and Nuclear Medicine,2004,28(6):265.

备注/Memo

备注/Memo:
收稿日期:2007-04-20。
基金项目:海南省卫生厅基金项目(200275)
通讯作者:李诗运,E-mail:yshli@csnm.com.cn
更新日期/Last Update: 1900-01-01